ArticleJournal of clinical medicine2022
Long Term Impact of Epicardial Left Atrial Appendage Ligation on Systemic Hemostasis:
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Exclusion of the left atrial appendage in Chinese population with perclip system: 1-year follow-up outcome results from a prospective, multi-center, open-label, single-arm device trial.Journal of cardiothoracic surgery · 2026Article
- A case with congenital absence of the left atrial appendage.Journal of arrhythmia · 2025Article
- The clinical impact of prophylactic concomitant left atrial appendage occlusion during cardiac surgery: A systematic review and meta-analysis.American heart journal plus : cardiology research and practice · 2025Article
- Device-Assisted Left Atrial Appendage Exclusion: From Basic Sciences to Clinical Applications.Journal of cardiovascular development and disease · 2024Review
- Detection and identification of factors in the atrium responsible for blood pressure regulation in patients with hypertension.Heart and vessels · 2024Article
- Long-term outcomes of left atrial appendage closure with or without concomitant pulmonary vein isolation:a propensity score matching analysis based on CLACBAC study.BMC cardiovascular disorders · 2024Article
- A decade later: long-term results of the first percutaneous epicardial closure of the left atrial appendage using the LARIAT device.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2023Article
- LARIAT or AtriClip: Complications Profile and Comparison in Patients with Atrial Fibrillations Based on Manufacturer and User Facility Device Experience Database.Medicina (Kaunas, Lithuania) · 2023Article
- Predicting the Absolute Risk of Ischemic Stroke in Asian Patients with Atrial Fibrillation: Comparing the COOL-AF Risk Score with CARS/mCARS Models for Absolute Risk and the CHA2DS2-VASc Score.Journal of clinical medicine · 2023Article
- Elevated thrombin generation levels in the left atrial appendage in patients with atrial fibrillation.Research and practice in thrombosis and haemostasis · 2023Article
- Safety and feasibility of left atrial appendage inversion in swine: A proof-of-concept study for potential therapy to prevent embolic stroke.Frontiers in bioengineering and biotechnology · 2023Article
- Sociodemographic disparities in concomitant left atrial appendage occlusion during cardiac valve operations.PloS one · 2023Article
- Left Atrial Myocardium in Arterial Hypertension.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundRecent data suggest that epicardial left atrial appendage closure (LAAC) is associated with several short-term neurohormonal effects. However, the long-term effects are currently unknown.
objectiveTo investigate the effects of percutaneous epicardial left atial appendage (LAA) exclusion using LARIAT on neurohormonal profiles at long-term follow-up.
methodsIn a prospective single centre study, 60 patients with long-standing, persistent atrial fibrillation (AF) LARIAT were treated. The major hormones of the adrenergic system, renin-angiotensin-aldosterone system (RAAS), and natriuretic peptides were assessed before the intervention and at regular intervals during the following two years.
resultsIn patients with epicardial LAAC, atrial natriuretic peptide (ANP) levels were significantly increased from baseline at 24 h and decreased at 7 days, 1 month, and 3 months, while remaining unchanged at 12 and 24 months. Noradrenaline levels were significantly lower at 24 h, 7 days, 1 month, 6 months, 12 months, and 24 months, while epinephrine levels decreased significantly at 1 month, 6 months, 12 months, and 24 months. Plasma renin activity significantly decreased at 7 days, 1 month, 6 months, 12 months, and 24 months, while aldosterone levels significantly decreased at 6 months, 12 months, and 24 months. Endothelin-1 and vasopressin showed a significant increase and decrease, respectively, at 24 h, 7 days, 1 month, 6 months, 12 months, and 24 months. There was also a significant decrease in systolic and diastolic blood pressure at 3 months, 6 months, 1 year, and 2 years after the intervention.
conclusionsEpicardial LAAC in AF patients is associated with persistent neurohormonal changes favouring blood pressure reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.